You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Claims for Patent: 11,220,541

✉ Email this page to a colleague

Summary for Patent: 11,220,541

Title:	CCL20 as a predictor of clinical response to IL23-antagonists
Abstract:	The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).
Inventor(s):	Georgantas, III Robert W., Morehouse Chris, Higgs Brandon, Ranade Koustubh, Streicher Katie, Rees William, Liang Meina, Faggioni Raffaella, Li Jing, Vainshtein Inna, Lee Yen-Wah, Chen Jingjing, Gasser, Jr. Robert A.
Assignee:
Application Number:	US16063803
Patent Claims:

Details for Patent 11,220,541

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	September 25, 2009	11,220,541	2036-12-16
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	December 30, 2009	11,220,541	2036-12-16
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	761044	September 23, 2016	11,220,541	2036-12-16
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	July 13, 2017	11,220,541	2036-12-16
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	January 29, 2019	11,220,541	2036-12-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.